FGEN has 36-month beta value of 0.72. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for FGEN is 94.13M, and currently, short sellers hold a 5.63% ratio of that float. The average trading volume of FGEN on March 18, 2025 was 3.61M shares.
FGEN) stock’s latest price update
The stock of FibroGen Inc (NASDAQ: FGEN) has decreased by -14.63 when compared to last closing price of 0.44.Despite this, the company has seen a loss of -8.04% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-17 that FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller – LifeSci Advisors Thane Wettig – CEO David DeLucia – CFO Conference Call Participants Andy Sieh – William Blair Matthew Keller – H.C. Wainwright Operator Hello everyone, and welcome to the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call.
FGEN’s Market Performance
FibroGen Inc (FGEN) has seen a -8.04% fall in stock performance for the week, with a -31.49% decline in the past month and a 11.05% surge in the past quarter. The volatility ratio for the week is 14.58%, and the volatility levels for the past 30 days are at 15.48% for FGEN. The simple moving average for the past 20 days is -17.72% for FGEN’s stock, with a -32.06% simple moving average for the past 200 days.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at -24.82% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.43% of loss for the given period.
Volatility was left at 15.48%, however, over the last 30 days, the volatility rate increased by 14.58%, as shares sank -35.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.15% lower at present.
During the last 5 trading sessions, FGEN fell by -9.22%, which changed the moving average for the period of 200-days by -67.95% in comparison to the 20-day moving average, which settled at $0.4615. In addition, FibroGen Inc saw -28.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Adib Deyaa, who purchase 22,123 shares at the price of $1.17 back on Jun 12 ’24. After this action, Adib Deyaa now owns 82,123 shares of FibroGen Inc, valued at $25,884 using the latest closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -0.63 for the present operating margin
- 0.77 for the gross margin
The net margin for FibroGen Inc stands at -0.68. The total capital return value is set at -1.53.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -5.35.
Currently, EBITDA for the company is -150.42 million with net debt to EBITDA at 0.52. When we switch over and look at the enterprise to sales, we see a ratio of -0.08. The receivables turnover for the company is 2.16for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.28.
Conclusion
To put it simply, FibroGen Inc (FGEN) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
